Vyleesi Injection
Product Images NDC 0713-0897

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Vyleesi (NDC 0713-0897). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cosette Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Vyl00 0004 01)

A forest plot chart showing pharmacokinetic ratios and 95% confidence intervals for various coadministered drugs. The y-axis lists drug names with pharmacokinetic parameters AUC and Cmax, while the x-axis represents ratio values ranging from 0 to 2. Data points with confidence intervals illustrate the relative exposure when these drugs are coadministered.*

FDA Label Image

Figure 2 (Vyl00 0004 02)

Two bar charts labeled Study 1 and Study 2 show the percentage of patients with increases in FSFI-Desire Domain scores from baseline to end of treatment, comparing Vyleesi injection (1.75 mg/.3mL) against placebo. The x-axis represents score increase ranges, and the y-axis shows the percentage of patients in each group.*

FDA Label Image

Figure 3 (Vyl00 0004 03)

Two bar charts comparing the percentage of patients with decreases in FSDS-DAO Q13 scores from baseline to the end of the treatment period in two separate studies of Vyleesi (bremelanotide) injection versus placebo. Each chart shows patient percentages across four levels of score decrease (≥1, ≥2, ≥3, and 4). The treatment group is indicated in black and placebo in white bars.*

FDA Label Image

Figure (Vyl00 0004 04)

Instructions for use text panel for Vyleesi (bremelanotide) injection, 1.75 mg per 0.3 mL, intended for subcutaneous use only. The panel features the proprietary and generic names with dosage strength and administration route details.*

FDA Label Image

Figure (Vyl00 0004 05)

Illustration showing parts of the Vyleesi (bremelanotide injection) 1.75 mg/0.3 mL autoinjector before and after use. The diagram highlights the expiration date, view window, and clear cap before use, and the purple window and purple tip indicating injection completion after use.*

FDA Label Image

Figure (Vyl00 0004 06)

FDA Label Image

Figure (Vyl00 0004 07)

An instructional illustration titled Step 1: Check Supplies, showing a prefilled Vyleesi injection pen or syringe with a pink cap inside a pink circle background.*

FDA Label Image

Figure (Vyl00 0004 08)

An instructional illustration showing a rear view outline of a human torso and legs highlighting the abdomen and thigh areas. The image emphasizes that the injection should be administered only into the stomach area (abdomen) or thigh for proper subcutaneous delivery.*

FDA Label Image

Figure (Vyl00 0004 09)

Instructional illustration showing Step 3: Prepare and Give Injection for Vyleesi (bremelanotide) injection. Panel A depicts twisting off the protective cap from the injection pen. Panel B shows the injection being administered subcutaneously into the abdomen.*

FDA Label Image

Figure (Vyl00 0004 10)

An instructional diagram illustrating the use of a subcutaneous injection for Vyleesi (bremelanotide) 1.75 mg/.3 mL. The images show a hand holding the injection pen against the skin, with directions to listen for the second click about 2 seconds after injection and to wait 5 seconds before removing the device.*

FDA Label Image

Figure (Vyl00 0004 11)

A text panel showing Step 4 of a set of instructions, titled 'Check That the Medicine was Given.' The text is a directive related to the administration or verification of medication, shown in large, clear black font on white background.*

FDA Label Image

Figure (Vyl00 0004 12)

An instructional diagram showing the tip of an injection pen with an arrow pointing to a small detail on the needle cap, emphasized by a magnified inset circle highlighting this area.*

FDA Label Image

Figure (Vyl00 0004 13)

Text panel showing Step 5 of a procedure titled 'Check the Injection Site'. The panel contains instructions focused on confirming the correct injection site for administration.*

FDA Label Image

Figure (Vyl00 0004 14)

An illustration depicting various adhesive bandages and wound dressings, including round bandages, rectangular adhesive strips, and a grid-patterned dressing. The items are arranged on a soft pink circular background, indicating items used for wound protection or after injection site care.*

FDA Label Image

Figure (Vyl00 0004 15)

An instructional diagram showing Step 6 for Vyleesi (bremelanotide) injection use, illustrating disposal instructions by throwing away the Vyleesi autoinjector into a sharps disposal container. The image includes a warning to keep the sharps disposal container out of reach of children.*

FDA Label Image

Figure (Vyl00 0004 16)

FDA Label Image

Principal Display Panel – 4 Syringe Carton Label (Vyl00 0004 18)

Packaging label for Vyleesi (bremelanotide injection) 1.75 mg/0.3 mL subcutaneous injection by Cosette Pharmaceuticals, Inc. The carton displays the proprietary and generic names, strength, route of administration, NDC 0713-0897, active and inactive ingredients, and manufacturer information. The design features black and light pink color blocks with the Cosette Pharmaceuticals logo and barcode.*

FDA Label Image

Principal Display Panel – Syringe Label (Vyl00 0004 19)

Label for Vyleesi (bremelanotide injection) 1.75 mg/0.3 mL single-dose autoinjector for subcutaneous use. The label includes storage instructions, usage limits, and states it is Rx only. Marketed by Cosette Pharmaceuticals, Inc. with NDC 0713-0897-06.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.